Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt
المؤلفون المشاركون
al-Kinaai, Najla
Zaghlul, Muhammad Sad
al-Zumur, Husam
Ahmad, Jihad
al-Minawi, Salma
Abd al-Wahhab, Mayy Amr
Fawzi, Muhammad
Rifat, Amal
Sulayman, Suniya
المصدر
Journal of the Egyptian National Cancer Institute
العدد
المجلد 30، العدد 1 (31 يناير/كانون الثاني 2018)، ص ص. 21-26، 6ص.
الناشر
جامعة القاهرة المعهد القومي للأورام
تاريخ النشر
2018-01-31
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Aim : The study aims to evaluate survival outcome in newly diagnosed pediatric intermediate risk neuroblastoma patients treated at the Children Cancer Hospital – Egypt and their relation to various clinical and pathological factors.
Methods : The study included stage 3 patients <1.5 years, children 1.5 years or older with stage 3 disease and favorable histopathological features, infants (<1 year) with International Neuroblastoma Staging System(INSS) stage 4 disease, stage 4 children 1–1.5 years with favorable biology, and infants stage 4 s (with unfavorable biologic features).
Patients received systemic chemotherapy, in the form of etoposide and carboplatin alternating with cyclophosphamide, doxorubicin and vincristine, administered at 3-week intervals, with a total of 6 or 8 cycles guided by reaching objective overall response (complete/very good partial/partial response).
Results : The study included 136 patients, 67 males and 69 females.
101 patients had abdominal primary tumors, 28 had mediastinal masss and 7 with masses in the neck; 68% were stage 3 and the remaining (n = 44) had metastatic disease.
The three-year overall survival (OS) and event-free survival (EFS) estimates were 94% ± 2% and 90.9% ± 2.5%, respectively.
OS and EFS by gender, age, pathology and INPC were all statistically not significantly different.
Moreover, OS for patients having surgery versus no surgery (inoperable residual only) was statistically significant (98.4% ± 1.6% & 88.7% ± 5.3%, respectively, p = .034).
Conclusion : A very high rate of survival is currently achievable in patients with intermediate risk neuroblastoma by chemotherapy or chemotherapy and surgery.
In addition to response, our plan is to adopt biologically-based treatment to reduce treatment-induced complications among survivors
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
al-Zumur, Husam& Ahmad, Jihad& al-Minawi, Salma& al-Kinaai, Najla& Rifat, Amal& Sulayman, Suniya…[et al.]. 2018. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute،Vol. 30, no. 1, pp.21-26.
https://search.emarefa.net/detail/BIM-788948
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
al-Zumur, Husam…[et al.]. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute Vol. 30, no. 1 (Jan. 2018), pp.21-26.
https://search.emarefa.net/detail/BIM-788948
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
al-Zumur, Husam& Ahmad, Jihad& al-Minawi, Salma& al-Kinaai, Najla& Rifat, Amal& Sulayman, Suniya…[et al.]. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute. 2018. Vol. 30, no. 1, pp.21-26.
https://search.emarefa.net/detail/BIM-788948
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 25-26
رقم السجل
BIM-788948
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر